1 A new synthetic bradykinin analogue was found to be an antagonist of bradykinin-induced vascular permeability in rabbit skin. It was effective in equimolar concentrations. 2 These analogues also antagonized the action of bradykinin in contracting the guinea-pig isolated ileum. The mean pA2 values of five different antagonists ranged from 5.3-6.4 respectively, on this preparation. 3 Our observations, together with those of others suggest that these antagonists act on the same receptor types, viz., B2, in rabbit blood vessels and in smooth muscle of guinea-pig ileum. 4 Our results support the view that the way is now promising for the synthesis of potent specific antagonists of bradykinin for experimental and therapeutic use.
Introduction
Bradykinin (BK) and related kinins are potent enhancers of vascular permeability (Holdstock et al., 1957; Bhoola et al., 1960; Bissett & Lewis, 1962; Uchida et al., 1983) . However, definite evidence of their involvement in inflammation has been uncertain, since effective antagonists have not been available. A number of BK analogues have recently been synthesized which are specific antagonists of BK on the guinea-pig isolated ileum. rat uterus and blood pressure (Table 1) , (Vavrek & Stewart, 1985) . Our findings support the observations of Vavrek & Stewart (1985) and, in addition, show that one ofthem, compound B-3824, is also an effective antagonist of BK-induced vascular permeability in rabbit skin. We selected it for our study since we found it more effective than compound B-3832, which in turn was more effective than compound B-3820 in the rabbit permeability test.
At least two receptor types have been proposed for kinins by Regoli & Barabe (1980) which they designated as B. and B2. The B. receptor is thought to be formed by de novo synthesis in vascular smooth muscle ex situ in particular, notably in the rabbit isolated (Regoli et al., 1978; Regoli & Barabe, 1980) . The B2 receptor is thought to mediate contraction of the rat uterus, cat and guinea-pig ileum (Barabe et al., 1977) . Subsequently Marceau et al. (1981) described B2 receptors for the increased vascular permeability caused by kinins in rabbit skin. Our results are consistent with the conclusion of Marceau etal. (1981) that this action of bradykinin is on receptors of the B2 type.
Some ofthese results have already been presented in a preliminary form (Longridge et al., 1986; ).
Methods
Hartley guinea-pigs (450-600g) and New Zealand white male rabbits (3-4kg) were anaesthetized with sodium pentobarbitone (Somnotol, MTC Pharmaceuticals, Hamilton, Canada) (30mg kg-') intraperitoneally (guinea-pigs) or intravenously (rabbits). In one set of experiments the rabbits were injected with a 5% solution of pontamine sky blue 6BX (BDH Chemicals Ltd, Poole) in 0.9% NaCl (1.0 ml kg-') via the marginal ear vein. The abdominal skin was shaved and depilated with 'Neet'. Solutions (agonists alone, or in combination with antagonist) were injected intradermally in a volume of0.1 ml 5 min after the injection of the pontamine sky blue. The rabbits were killed 40 min later by exsanguination, the appropriate areas of skin removed, and the dye extracted from each blue injection site and measured by the spectrophotometric method of Katayama et al. (1978) . In another set of similar experiments on vascular permeability, the rabbits were unanaesthetized, pretreated with captopril (Squibb) (I mg kg-' s.c.) to enhance the effect of bradykinin, injected with Evans blue dye (Sigma) (lOmgkg' i.v.), and measurements of cutaneous dye extravasation were made from the mean diameter of the lesion after animals had been killed by an overdose of sodium pentobarbitone, given intravenously.
Contractions of the guinea-pig isolated ileum bathed in Tyrode solution (containing atropine sulphate and mepyramine maleate, 10-6 M) were recorded isometrically with a force displacement transducer. Vavrek & Stewart, 1985) were dissolved in sterile Tyrode solution and subsequent dilutions made in Tyrode solution before use. Angiotensin II (All, Sigma), 5-hydroxytryptamine (5-HT, Sigma), substance P (SP, Sigma) and des-Arge-[Leu8J BK (Peninsula Lab. Inc., San Carlos, CA) were similarly dissolved.
Results
The primary structures of the new BK antagonists and their relative potencies in antagonizing the effect of bradykinin in contracting the guinea-pig isolated ileum are shown in Table 1 . Their mean pA2 values ranged from 5.3-6.4, compound B-3824 being the most potent with a mean pA2 value of 6.4. This BK analogue has amino acid replacements at positions proline-3, phenylalanine-5, proline-7 and phenylalanine-8, with L-4-hydroxyproline (Hyp), ,-2-thienyl-Lalanine (Thi), D-phenylalanine (D-Phe) and P-2-thienyl-L-alanine (Thi) respectively. In addition to these replacements, D-arginine is added to the Nterminal residue (Table 1) .
Figures 1-3 show the effects of BK and of the BK antagonist B-3824 on vascular permeability in rabbit skin in our experiments using anaesthesia, pontamine blue dye, and measuring the dye extracted from the skin lesions. Figure 1 shows the dose-response curves of BK, L-BK and histamine in rabbit skin. Those for BK and L-BK are identical in the dose range used (0.01 -10 nmol 0.1 ml'). The curve for histamine (1.0-1000 nmol 0.1 ml-'), however, is shifted well to the right indicat- ing a much lower potency. AII, 5-HT, SP and desArg9 BK, were even less effective than histamine. Figure 2 shows the result of a typical experiment in which BK (0.01-10nmol injected intradermally in 0.1 ml) increased vascular permeability in rabbit skin. It also shows the effect of a range of concentrations of the antagonist B-3824 when injected together with 1.0 mol BK. Similar results were obtained in five rabbits. It was apparent that this antagonist in a concentration of 1 nmol 0.1 ml-' reduced the increase in vascular permeability caused by 1.Onmol BK to that of 0.1 nmol. Even with as little as 0.1 nmol antagonist, a reduction in the effect of 1.0 nmol BK was seen. Tyrode solution alone was without effect. Higher concentrations of the antagonist B-3824, (e.g. 100 nmol) showed an agonist effect (Figure 2) . Figure 3 was derived from results on 2 rabbits in which randomized injections of BK alone, or with antagonist B-3824, were made intradermally ( Figure  2 ). The responses to 5 doses of BK (0.01-10 nmol 0.1 ml-') were obtained and the effect of 5 different doses of the BK antagonist B-3824 (0.01-100 nmol 0.1 ml-') on the response to a standard dose of BK (1.0 nmol 0.1 ml-') determined. The intradermal injection of as little as 0.1 nmol B-3824 significantly reduced the increase in permeability induced by 1 nmol BK (P <0.05). Also, 1 nmol B-3824 reduced the effect of 1 nmol BK to that induced by 0.1 nmol (see also Figure 2 ). Figure 3 also shows that 10 nmol B-3824 had no agonist activity, but agonist activity appeared at higher doses, e.g. 100 nmol.
In 2 rabbits, and using the above technique, the selective B. antagonist des-Arg9-[Leu8] BK (Regoli & Barabe, 1980) (O.1-100 nmol 0.1 ml-') was found not to reduce the effect of an intradermal injection of BK (1 nmol 0.1 ml-').
Similar results were obtained with the BK antagonist B-3824 in unanaesthetized rabbits (see Methods) as those in the anaesthetized rabbits. In these experiments, in which conditions were somewhat different, and in which the diameter of the extravasated dye around the injection site was simply measured in mm, 10 nmol B-3824 completely abolished the response to 0.1 nmol BK. The mean lesion diameter of 11.3 ± 0.4 mm was reduced to zero, or immeasurable size at these doses of BK and antagonist. These values are the results of 12 measurements each for BK alone and for BK plus B-3824 in 4 unanaesthetized rabbits. Unlike the anaesthetized rabbits, no agonist activity was observed after an injection of 100 nmol B-3824; this may be due to the different conditions, particularly in the use of a different dye (Evans blue) to detect the increased vascular permeability. 
Discussion
Our results show that the BK antagonist B-3824 is not only an antagonist of BK-induced contraction of the guinea-pig isolated ileum but is also effective against BK-induced vascular permeability in blood vessels of rabbit skin. If B-3824 proves to be as effective in human skin as it is in that of rabbit, and particularly should it prove effective against the pain-producing effects of BK in man (Armstrong et al., 1957; Holdstock et al., 1957; Schachter, 1960) , it could be a useful anti-inflammatory or analgesic agent. We did not test the specificity of these antagonists against other peptides since All and SP proved to be ineffective in increasing vascular permeability in the rabbit. However, it has been shown by Vavrek & Stewart (1985) that although B-3824 is a potent inhibitor of BK on the rat uterus and guinea-pig ileum preparations, it is ineffective against All and SP on these Tyrode. The results were derived from 2 rabbits. In one rabbit each dose was repeated 4 times, in the other 3 times; making a total of 7 tests for each dose from which the means were derived. Effect ofinjections ofTyrode solution alone, or plus B-3824, is the mean effect of 4 injections, 2 in each rabbit.
preparations. It would appear therefore that these BK analogues are specific inhibitors of BK.
Although the classification of BK receptor types is still unsettled (Whalley et al., 1984; Boschov et al., 1984) (Figure 3 ). It showed no agonist actions of its own at this concentration, and even 10 times this concentration, 10nmol 0.1 ml', had no agonist activity However, at a much higher dose (100 nmol) some agonist activity was noted. Since only 4 pairs of matched controls were carried out at this concentration, the formal P value of< 0.1 is oflimited significance. Indeed, complete inhibition of the increased permeability caused by BK was observed without agonist activity when similar experiments were carried out under different conditions. In the latter instance tests were made in rabbit skin but without anaesthesia, using a different dye (Evans blue), and measuring the diameter of exuded dye rather than the amount of dye extracted.
Finally, our results support the veiw of Vavrek & Stewart (1985) that the development of effective bradykinin antagonists has begun. The available evidence indicates that this inhibition is competitive and specific and that new compounds will be synthesized. They should prove to be valuable tools for the investigation of the roles of kinins in physiology and pathology as well as for their possible therapeutic use in man.
